Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 4 n* \& J4 N0 n1 m; u
9 m5 c+ e5 t) {3 n
( p% r3 b7 [' A" sSub-category:+ _8 O, |/ K, Y5 u' Q M1 `0 d
Molecular Targets
`3 d& u8 ]7 ~$ j3 V0 @8 @2 f& b" W. Q( d/ Q& F- d4 X
, b5 z$ {3 D. v) L, q) F
Category:
3 F2 Y; O1 U& a6 R; H" VTumor Biology
9 V6 N6 l& F- g% N; L# O3 |% f/ r9 P7 x( A$ f
: ^4 ^" S! j; O. ~" Q
Meeting:5 E5 C6 c6 X0 K$ X+ }
2011 ASCO Annual Meeting 0 r+ N2 Z0 y* W! P* y9 q
" t7 _% v$ @5 f
8 q: b3 E4 k' ~' }. R5 i( dSession Type and Session Title:* u% j8 B$ _9 b2 Z0 o- r @4 l) j$ m
Poster Discussion Session, Tumor Biology
& g' Q% b% q# z9 Z" g1 P7 ~& X2 a" S: U6 S) T
8 g/ m3 i S3 |7 ^& u1 W' O( bAbstract No:" z8 ?! ]6 m2 k
10517 . c9 h) O& W3 j4 w4 a4 d! m6 K
0 z0 g p; b- i X* l0 M
* P4 m/ `: k' p% F( ]% L( ?
Citation:, Q9 a; u4 u, w$ J" Y6 T n C
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. D; y2 }# G9 @
9 p S! m8 X- B d2 w' l' S; z5 G5 a3 O/ N* l
Author(s):$ ^' C7 J: M* Z- c* G8 r5 S5 m0 ?# ?
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ ^$ ^% g1 H- P! p" R7 _' P! z4 J! g2 C( C1 t% M9 e
) L8 P6 Y8 g2 j, @
- Z4 [! D' Q/ ~" ^: ?Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.9 X+ u: h1 w4 r. K
5 l. T' d4 ~7 u; @2 X i1 o8 y
Abstract Disclosures
8 u$ C0 F! Q7 v3 V/ |, p% U1 x
9 U$ @' \+ s- R/ u) c0 OAbstract:' N/ h' J. e+ x, N" e+ A+ s( S
& L# z3 a3 ^2 N5 J, V1 w
; p8 m# u/ ]0 A% Q) P3 g7 c6 LBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.- f, D2 c: E3 ?# Q: `, t9 v2 n
- @. A) v7 N. v' i }7 D0 K
4 y& x5 p, ^7 `* `2 G2 O$ M" J6 ~" q |